BCL2A1 Human

The BCL2A1 gene is located on chromosome 15q25.1 in humans . The protein encoded by this gene consists of 176 amino acids and has a molecular mass of approximately 20.2 kDa . The BCL2A1 protein contains BH (Bcl-2 homology) domains that are essential for its function in apoptosis regulation .

BCL2A1 is an anti-apoptotic protein that plays a significant role in preventing cell death by inhibiting the release of cytochrome c from the mitochondria into the cytosol . This inhibition blocks the activation of caspases, which are proteases that execute apoptosis . BCL2A1 is involved in various cellular processes, including embryonic development, immune response, and tumorigenesis .

The expression of BCL2A1 is regulated by several extracellular signals such as granulocyte-macrophage colony-stimulating factor (GM-CSF), CD40, phorbol ester, and inflammatory cytokines like TNF and IL-1 . It is also a direct transcription target of NF-kappa B in response to inflammatory mediators .

BCL2A1 has been implicated in various diseases, particularly hematologic cancers and leukemia . Its anti-apoptotic function contributes to the survival of cancer cells, making it a potential target for cancer therapy. The protein’s role in immune response and inflammation also suggests its involvement in autoimmune diseases and chronic inflammatory conditions .

Recombinant human BCL2A1 is produced using E. coli expression systems and is used in research to study its function and potential therapeutic applications . The recombinant protein retains the functional properties of the native protein, making it a valuable tool for biochemical and pharmacological studies.